CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
Furthering cell therapy ambition across oncology and autoimmune diseases
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100m.
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
Subscribe To Our Newsletter & Stay Updated
